Numerous functional carbon materials have been investigated as electrodes for the detection of (bio)chemical analytes in electrochemical assays. The electroanalytical performance of these materials is strongly influenced by the structural properties of the carbon itself which is mainly attributed to the density of electronic states as well as the edge-plane sites available on the surface. Of all carbon materials, graphene has emerged as the most promising candidate.
Embodiments of the present disclosure provide for on-chip electrode platform devices and methods of making on-chip electrode platform devices and the like, which can be used for biosensing of biological targets and the like.
An embodiment of the present disclosure includes on-chip electrode platforms disposed on a substrate, comprising a plurality of electrodes, wherein at least one of the electrodes is a three dimensional laser scribed graphene electrode that has a self-standing macro/mesoporous three dimensional morphology.
An embodiment of the present disclosure also includes methods of making an on-chip electrode platform, in which a laser beam is directed onto a substrate, and a three dimensional laser scribed graphene electrode is formed that has a self-standing macro/mesoporous three dimensional morphology.
Other apparatus, structures, methods, features, and advantages will be or become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional apparatus, structures, methods, features and advantages be included within this description, be within the scope of the present disclosure, and be protected by the accompanying claims.
Further aspects of the present disclosure will be more readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings.
This disclosure is not limited to particular embodiments described, and as such may, of course, vary. The terminology used herein serves the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
Where a range of values is provided, each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of material science, chemistry, biology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform, make, and use the embodiments disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.
Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, dimensions, frequency ranges, applications, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence, where this is logically possible. It is also possible that the embodiments of the present disclosure can be applied to additional embodiments involving measurements beyond the examples described herein, which are not intended to be limiting. It is furthermore possible that the embodiments of the present disclosure can be combined or integrated with other measurement techniques beyond the examples described herein, which are not intended to be limiting.
It should be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a support” includes a plurality of supports. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.
“Aptamers” may be high affinity, high specificity polypeptide, RNA, or DNA-based probes produced by in vitro selection experiments. Aptamers may be generated from random sequences of nucleotides or amino acids, selectively screened by absorption to molecular antigens or cells, and enriched to purify specific high affinity binding ligands, for example. In solution, aptamers may be unstructured but may fold and enwrap target epitopes providing specific binding recognition. The unique folding of the nucleic acids around the epitope, for example, affords discriminatory intermolecular contacts through hydrogen bonding, electrostatic interaction, stacking, and shape complementarity.
Use of the phrase “biomaterial” or “biomolecule” is intended to encompass at least deoxyribonucleic acid (DNA), ribonucleic acid (RNA), nucleotides, oligonucleotides, nucleosides, polynucleotides, proteins, peptides, polypeptides, selenoproteins, antibodies, antigens, protein complexes, aptamers, combinations thereof, and the like.
Use of “biological target” is intended to encompass biomolecules (e.g., deoxyribonucleic acid (DNA), ribonucleic acid (RNA), nucleotides, oligonucleotides, nucleosides, polynucleotides, proteins, peptides, polypeptides, selenoproteins, antibodies, antigens, protein complexes, aptamers, combinations thereof), and the like. In particular, biological target can include, but is not limited to, naturally occurring substances such as polypeptides, polynucleotides, lipids, fatty acids, glycoproteins, carbohydrates, fatty acids, enzymes, fatty esters, macromolecular polypeptide complexes, vitamins, co-factors, whole cells, eukaryotic cells, prokaryotic cells, micelles, microorganisms such as viruses, bacteria, protozoa, archaea, fungi, algae, spores, apicomplexan, trematodes, nematodes, mycoplasma, or combinations thereof. In addition, the biological target can include native intact cells, viruses, bacterium, and the like.
Use of the term “affinity” can include biological interactions and/or chemical interactions. The biological interactions can include, but are not limited to, bonding or hybridization among one or more biological functional groups located on the first biomolecule or biological target and the second biomolecule or biological target. The chemical interaction can include, but is not limited to, bonding among one or more functional groups (e.g., organic and/or inorganic functional groups) located on the biomolecules.
As used herein, “targeting agent” is intended to encompass any molecule, including but not limited to aptamers, a chemical agent, a biological agent (e.g., polypeptides (e.g., proteins such as, but not limited to, antibodies (monoclonal or polyclonal), fragments of antibodies), antigens, nucleic acids (both monomeric and oligomeric), peptoids, polysaccharides, haptens, sugars, fatty acids, steroids, purines, pyrimidines, ligands, and aptamers) and combinations thereof, having an affinity for a biological target.
Embodiments of the present disclosure provide a device including an on-chip electrode platform including one or more three dimensional laser scribed graphene electrodes, methods of making the on-chip electrode platform, methods of analyzing (e.g., detecting, quantifying, and the like) chemicals and biochemicals, and the like. Embodiments of the present disclosure relate to large scale fabrication of an on-chip electrode platform fabricated by direct growth of a porous binder free three dimensional graphene architectures on substrates (e.g., polyimide) employing laser scribing of the surface of the substrate.
In particular, embodiments of the present disclosure include large scale flexible electrochemical sensors that can be fabricated by adopting direct growth of graphitic carbon patterns on a substrate, such as a commercial polyimide surface, by use of a laser scribing approach, where the material modification can be referred to as laser scribed graphene (LSG). Embodiments of the present disclosure are beneficial in that large-scale fabrication of a chemical or biosensor device with three dimensional porous binder free graphene networks as active material can be produced, where the on-chip electrodes of the platform exhibit superior electrochemical activity and sensing properties. In an embodiment, the on-chip electrodes can be used to precisely monitor the dopamine, ascorbic acid and/or uric acid levels in a sample(s) with minimum interference, which is described in more detail in the Examples. As compared to some systems, embodiments of the present disclosure are free from enzymes, so that the on-chip electrode platform can be stored at room temperature and reused several times without any passivation effect.
An embodiment of the device includes an on-chip electrode platform that is disposed on a substrate. The on-chip electrode platform includes a plurality of electrodes, where at least one of the electrodes is a three dimensional laser scribed graphene electrode that has a self-standing macro/mesoporous three dimensional morphology. The laser scribed graphene includes self-standing macro/mesoporous three dimensional morphology with ample amount (e.g., greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 25%, about 5 to 30%, about 15 to 30%, about 15 to 25%, or about 19 to 22%) of edge plane sites and large (e.g., the surface area determined by the Randles-Sevcik plot (
In an embodiment, the macro/mesoporous three dimensional morphology includes a macroporous surface with a mesoporous porous architecture superimposed on the surface of the macroporous surface. In other words, there is a mesoporous network of pores on the macroporous surface. In an embodiment, the macroporous surface includes pores having a diameter of about 50 nm or more (e.g., in the μm range or higher) and the mesoporous porous architecture includes pores having a diameter of about 2 nm to 10 nm. In an embodiment, the macropores can extend to a depth of about 10 μm to 50 μm of the electrode. In an embodiment, the pores can be straight or winding and/or branched or unbranched and the diameter can vary at different depths of the pores.
In an embodiment, the self-standing macro/mesoporous three dimensional morphology can include a three dimensional network of micron size graphene flakes. The macro porosity of the network facilitates electrolyte diffusion into porous network that results in about a 30% enhancement of electrochemical active surface area compared to physical surface area of the LSG electrode. The cross-sectional SEM images reveal an ordered-porous morphology, and including this, the graphene flakes exhibit mesoporous structures that facilitates ion diffusion leading to better catalytic activity compared to commercial graphite electrodes.
In an embodiment, the substrate can be a material that forms three dimensional laser scribed graphene upon exposure to a laser beam. The focused laser beam produces very high local temperatures (e.g., greater than about 2500° C.), which helps in carbonization and graphitization of the surface of the substrate. In an embodiment, the substrate can be a substrate having polyimide polymer surface thick enough to form the electrode. In an embodiment, the polymer layer or the polymer substrate can include a polymer having heterocyclic structures such as the imide group. In an embodiment, the polymer layer or the polymer substrate can include: polyimide, as well as other polymers including heterocyclic structures (e.g., imide group) or a combination thereof.
In an embodiment, the three dimensional laser scribed graphene electrode can have a thickness of about 10 μm to 50 μm or about 30 to 36 μm or about 33 μm. The other dimensions can be appropriate for the electrode being formed as well as the overall design of the electrode platform, so that so length and width can be selected according to the design of the electrode platform, for example the width can vary as a function of location on the electrode. In general the length and width are on the order of mm's to cm's.
In an embodiment, the device includes a multi-electrode platform (e.g., a three electrode platform (counter electrode (CE), working electrode (WE) and electrode (E or RE)) where each electrode is made up of three dimensional porous graphene sheets patterned over substrate (e.g., See
In an embodiment, one or more of the electrodes can include one or more types of particles disposed on a surface of the electrode to modify the functioning of the electrode. For example, the particles may enhance sensitivity and/or selectivity to one or more chemical or biochemical species of interest. In an embodiment, an area of the working electrode can be defined (isolated) by selective passivation from rest of the pattern (e.g., by PDMS coating) so that the working electrode can be selectively modified on a selected surface area, or the reactive portion of the electrode.
For example, the working electrode can be modified by selective disposition (e.g., anchoring (e.g., attaching or bonding to the nanoparticles over the graphene layer)) of metal nanoparticles (e.g., Pt nanoparticles) by electrodeposition or other appropriate technique that accomplishes the same or similar result. In an embodiment, the particles can include metal nanoparticles such as transition metal nanoparticles, Pt nanoparticles, Cu nanoparticles. Ni nanoparticles, Zn nanoparticles, Ag nanoparticles. Au nanoparticles, Pd nanoparticles. Ru nanoparticles, oxides of each (e.g., CuO, NiO, ZnO), metal hydroxides of each (e.g., Cu(OH)2, Ni(OH)2), oxynitrides of each, and the like. In an embodiment, the nanoparticles have a diameter (for spherical-shaped particles, and if non-spherical, then these dimension correspond to each of height, length, and width) of about 1 to 500 nm, about 10 to 250 nm, or about 10 to 100 nm.
In another embodiment, the working electrode can be modified by selective disposition (e.g., anchoring (e.g., attaching or bonding to the graphene layer)) of a targeting agent to the surface of the working electrode. In an embodiment, the targeting agent can attach (e.g., be bound to the substrate) to (directly or indirectly) the working electrode. In an embodiment, the targeting agent can include biomolecules (e.g., deoxyribonucleic acid (DNA), ribonucleic acid (RNA), nucleotides, oligonucleotides, nucleosides, polynucleotides, proteins, peptides, polypeptides, selenoproteins, antibodies, antigens, protein complexes, aptamers, combinations thereof), and the like. In particular, the biological target can include, but is not limited to, naturally occurring substances such as polypeptides, polynucleotides, lipids, fatty acids, glycoproteins, carbohydrates, fatty acids, enzymes, fatty esters, macromolecular polypeptide complexes, vitamins, co-factors, whole cells, eukaryotic cells, prokaryotic cells, micelles, microorganisms such as viruses, bacteria, phage, protozoa, archaea, fungi, algae, spores, apicomplexan, trematodes, nematodes, mycoplasma, or combinations thereof. In addition, the biological target can include native intact cells, viruses, bacterium, and the like. In general, the targeting agent has an affinity for a biological target that is to be detected.
In an embodiment, the targeting agent can be attached or bonded (directly or indirectly) to the surface of the working electrode by a physical, biological, biochemical, and/or chemical association. The terms “attach” or “bond” can include, but are not limited to, chemically bonded (e.g., covalently or ionically), biologically bonded, biochemically bonded, and/or otherwise associated with the particle. In an embodiment, bond can include, but is not limited to, a covalent bond, a non-covalent bond, an ionic bond, a chelated bond, as well as being bound through interactions such as, but not limited to, hydrophobic interactions, hydrophilic interactions, charge-charge interactions, π-stacking interactions, combinations thereof, and like interactions.
In an embodiment, the targeting agent can be directly bonded to the surface of the working electrode and/or to particles on the surface of the working electrode.
In an embodiment, the targeting agent can be indirectly bonded to the surface of the working electrode and/or to particles using a linking agent. The linking agent functions to bond to the working electrode and/or to particle and also bond to the targeting agent. The linking agent includes, but is not limited to, particles, nanomaterials, and molecules binding covalently (such as diazonium salts, nitrophenyls and benzoyl peroxide) or non-covalently to the graphene surface. In the latter case, molecules can bind to the graphene via r-T stacking, ionic bonding, hydrogen bonding, hydrophobic or electrostatic interactions.
Examples include polymer wrapping, adsorption of surfactants, and binding of small aromatic compounds. Examples include sulfonated polyaniline, poly(sodium 4-styrenesulfonate), pyrene butyric acid.
Embodiments of the present disclosure can be fabricated by adopting direct growth of graphitic carbon patterns on a substrate employing a laser scribing approach. The focused laser beam could produce very high local temperatures (e.g., greater than about 2500° C.), which helps in carbonization and graphitization of the surface of the substrate (e.g., polymer surface) to form the electrode platform. The laser(s) can be used to form one or more three dimensional laser scribed graphene electrode that include self-standing macro/mesoporous three dimensional morphology. The time frame of exposure as well as the power of the laser can be used to form the desired dimensions and/or characteristics of the electrode(s). In an embodiment, the laser can include commercially used lasers that are in the 2.4 to 5.4 W range. In an embodiment, the time of exposure of the surface to the laser can be about 0.003 to 1.3 s.
As mentioned above, particles, such as nanoparticles, can be disposed on one or more areas of the three dimensional laser scribed graphene electrode. In an embodiment, one or more types of particles (e.g., metal nanoparticles) can be disposed on one or more areas of the three dimensional laser scribed graphene electrode. In an embodiment, Pt nanoparticles can be disposed on a working electrode. In an embodiment, the particles can be disposed using electrodeposition, electrodeposition, chemical reduction, microwave irradiation, or hydrothermal to anchor the particles to the electrode surface.
As mentioned above, embodiments of the present disclosure can be used to detect one or more chemical or biochemical. Embodiments of the present disclosure exhibit superior electrochemical activity and sensing properties as compared to some techniques. As describe in detail in the Example, an embodiment of the on-chip platform including three electrodes can be used to monitor the dopamine, ascorbic acid and/or uric acid levels in a sample(s) with minimum interference, where the results are comparable or superior to other techniques. Also, due to the simplicity of the present disclosure, the on-chip electrode platform can be stored at room temperature and reused.
In electrochemical sensing applications and commercialization, the electrodes having high electrochemically active surface area, good charge transfer behavior, a broad detection range with high sensitivity and selectivity and finally a scaled up fabrication technique is highly desired.
In an embodiment, the average charge transfer coefficient (k0) value for laser scribed graphene electrode can be about 0.0044 cm·s−1 (e.g., 0.0044+0.0003 cm·s−1) for hexacyanoferrate (II/III) in PBS, demonstrating a favorable electron transfer rate in the case of three dimensional porous laser scribed graphene electrode. The enhancement is believed to be a combined consequence of the porous, binder free three dimensional network of laser scribed graphene electrode with large intrinsic protrusions of graphene sheets and rich in edge plane sites which, in turn, activate the graphene surface toward enhanced electrochemical reactions. In an embodiment, the charge transfer coefficient was further enhanced by incorporation of Pt NPs on laser scribed graphene electrode. The calculated k0 value for Pt/laser scribed graphene electrode is 0.2823 cm/s which elucidates the catalytic behavior of Pt NPs on the surfaces of the laser scribed graphene electrode facilitating the charge transfer mechanism.
In an embodiment, the laser scribed graphene electrode based electrode patterns have exhibited significantly improved electrocatalytic performance toward oxidation of ascorbic acid, dopamine and uric acid displaying high sensitivity, selectivity in a wide concentration range (See
Embodiments including high electrochemically active surface area, efficient charge transfer behavior and high repeatability of electrode material, provide for laser scribed graphene electrodes that can be used as a potential electrode material for different bio-analyte detection in broad range. Also, the laser based scaled-up fabrication technique provides the advantage in large scale commercialization for practical application.
The following examples are directed to large scale fabrication of on-chip electrode platform based on direct growth of porous binder free three dimensional graphene architectures on commercial polyimide (PI) sheet employing laser scribing and its application towards detection of biomolecules. An embodiment of the on-chip electrode platform is provided in
The on-chip device structure includes a three-electrode platform (counter electrode (CE), working electrode (WE) and electrode (E or RE)) made up of 3D porous graphene sheets patterned over flexible PI sheet, as shown in
The electrochemistry of LSG based electrodes were thoroughly investigated before implementing it as a biosensor platform.
The electrochemical active surface area (A) for LSG and Pt/LSG electrodes were estimated based on the Randles-Sevcik equation, which assumes mass transport only by diffusion process.
Ip=2.69×105AD1/2n3/2υ1/2C (1)
Where n is the number of electrons participating in the redox reaction, D is the diffusion coefficient of the molecule (D=6.70×10−6 cm2/s for [Fe(CN)6]4− and 8.43×10−6 cm2/s for [Ru(NH3)6]3+), C is the concentration of the probe molecule in the solution (mol/cm3), and is the scan rate (V/s). Using the experimental parameters, the calculated electrochemical active surface area A value for the LSG electrode was found to be ˜9.177 mm2 which is ˜30% enhancement compared to physical surface area of the LSG electrode (7.065 mm2). Also the calculated average A value for the Pt/LSG is ˜10.383 mm2. Thus, the addition of Pt nanoparticles increased the effective electrode surface area by roughly 13.14%.
A reproducible redox current observed for five different LSG electrodes indicates the repeatability of the fabricated microelectrodes (
The average charge transfer coefficient (k0) value is calculated to be 0.1150 cm/s (
As described herein, embodiments of the present disclosure pertain to the large-scale fabrication of on-chip electrode platforms based on direct growth of porous binder free three dimensional graphene architectures on commercial PI sheet its application towards biosensing. Based on the above discussed electrochemical performances, the LSG based electrode was employed for the potential detection of biologically promising analytes such as dopamine (DA), ascorbic acid (AA) and/or uric acid (UA). DA is one of the important neurotransmitter in the mammalian central nervous system. Any abnormality leads to severe neurological disorders such as Parkinson's disease and Schizophrenia, and hence is a key marker for the treatment of these diseases. AA is well-known for its antioxidant properties and plays a key role in biological metabolism. UA is an important natural antioxidant produced when the body breaks down purines. Abnormal levels of UA are symptomatic of hyperuricemia and several kidney diseases. Because UA, DA, and AA coexist in the central nervous system and the electrochemical oxidation peak potentials overlap at conventional solid electrodes, the primary challenge encountered here is to separate their oxidation peak potentials with enhanced intensity.
The typical DPV response of the LSG electrode to the addition of different concentrations of DA, UA and AA in PBS solution is shown in
The LSG electrodes were also used to detect thrombin successfully. In fad, our initial results show that it can detect thrombin down to the nano molar level (
Graphene as transducer material has produced some of the best-performing sensing approaches to date opening the door toward integrated miniaturized all-carbon point-of-care devices. Addressing this opportunity, laser-scribed graphene (LSG) electrodes are demonstrated here as highly sensitive and reliable biosensor transducers in blood serum analysis. These flexible electrodes with large electrochemical surface areas were fabricated using a direct-write laser process on polyimide foils. A universal immobilization approach is established by anchoring 1-pyrenebutyric acid to the graphene and subsequently covalently attaching an aptamer against the coagulation factor thrombin as an exemplary bioreceptor to the carboxyl groups. The resulting biosensor displays extremely low detection limits of 1 μM in buffer and 5 μM in the complex matrix of serum.
Numerous functional carbon materials have been investigated as electrodes for the detection of (bio)chemical analytes in electrochemical assays.1-3 The electroanalytical performance of these materials is strongly influenced by the structural properties of the carbon itself which is mainly attributed to the density of electronic states as well as the edge-plane sites available on the surface.4,5 Of all carbon materials, graphene has emerged as the most promising candidate.6,7 Its water-dispersible derivatives, such as graphene oxide, are often used for the modification of electrodes but even when reduced through (physico)chemical means8-10 the outstanding electrochemical properties of pristine graphene cannot be achieved due to numerous structural defects in graphene oxides.11 To bridge the existing gap between lab research and commercial graphene-based biosensors, reliable, scalable fabrication and modification methods are still needed.12 Here, standalone graphene electrodes can be a promising solution. EI-Kady et al.13 have introduced a novel and straightforward method to produce supercapacitors made of graphene by the direct laser reduction of graphene oxide with a standard LightScribe DVD optical drive. The resulting films—referred to as laser-scribed graphene (LSG)—show high electrical conductivity and specific surface area, are mechanically robust, and can be used directly as capacitor electrodes without the need of additives. In a following study,14 Strong et al. built a low-cost graphene-based NO2 gas sensor besting conventional carbon electrodes due to the LSG's superior electrical conductivity. Further, LSG can be easily printed, scaled, and is flexible.15,16 Combined with the high electron transfer rates, small peak potential differences and a good peak current response,5,13,14 it is extremely interesting for a broad range of biosensing applications including, but not limited to complex clinical diagnostics and implantable sensing arrays. LSG offers the possibility to create flexible, all-printed and implantable microarrays of electrodes with high surface area for the detection of multiple analytes such as biomarkers,17 neurotransmitters,18 proteins or other biomolecules.19 To move LSG into the arena of biosensing, a reliable route for its modification with various biorecognition elements is required.20 Here we demonstrate a universal modification route for LSG electrodes by anchoring 1-pyrenebutyric acid (PBA) via n-stacking and hydrophobic interactions to the LSG and subsequently covalently attaching bioreceptors to the carboxyl groups using standard coupling chemistry. An LSG-based electrochemical biosensor for thrombin (
Laser-scribed graphene compares favorably to other carbon devices with respect to combining high electron transfer rates, small peak potential differences and a good peak current response with fast and scalable fabrication.5,14 As it doesn't require fabrication masks or elaborate lithography equipment, which is the case for screen-printed electrodes and most microfabricated electrochemical biosensors, respectively, it is a highly attractive choice for electrochemical sensing (
Scanning electron micrographs of the top-view of the electrode (
Raman spectroscopy was used to prove the quality of the laser-scribed 2D-nanomaterial.
Initial studies of the modification protocol revealed that pristine LSG does not possess enough functional groups for adequate immobilization of anti-thrombin aptamer (
Starting with the bare LSG electrode, the peak current of the unmodified electrode is as high as 130 μA due to an unhindered diffusion of the redox marker hexacyanoferrate(II/II) to the electrode surface. Upon addition of the first layer consisting of 1-pyrenebutyric acid, the peak current decreases to 57.5±0.2% of the original value of non-modified LSG. After coupling of the amino-functionalized anti-thrombin aptamers to the carboxyl groups, the peak current further decreases to 34.2+0.4% indicating the successful modification of the laser-scribed graphene electrode with the biorecognition elements.
In order to quantify the thrombin sensing properties of such modified LSG electrodes, the device was immersed into PBS containing thrombin in varying concentrations from 1 to 100 μM. Equilibration time was found to be at an optimum at 30 min which is faster than comparable approaches using redox-tagged aptamers23 or an impedimetric sensing scheme.24 After rinsing the electrode with PBS, it was placed in the electrochemical cell for DPV measurements. As expected, upon binding of thrombin to the aptamers, the available electrode surface for the redox marker is reduced resulting in decreasing DPV peak currents upon increasing thrombin concentrations. Thrombin binding to the LSG electrodes shows a saturation behavior common for antigen-antibody or antigen-aptamer interactions. Using the logarithmic concentration scale (
With its low limit of detection (LOD) of 1 pM and its high sensitivity of −2.41±0.16 μA·cm−2 per logarithmic concentration unit, this sensor is particularly useful when measuring pathological thrombin concentrations below the nanomolar level as found in healthy patients.23 In fact, it compares favorably to the performance of other carbon-based thrombin sensing schemes with higher LODs (Table 3).24-26
Furthermore, aptamer-functionalized LSG excels at electrode-to-electrode reproducibility. The largest variation of four individual electrodes is 2.2% of the mean signal change at a thrombin concentration of 10 pM.
The signal change of this sensing setup is based on the specific binding of thrombin to the immobilized aptamers and the resulting hindrance of diffusion of the redox marker. However, non-specific binding of interfering substances such as other proteins can also impede this diffusion and thus lead to a decrease in the DPV peak current. Therefore, interference studies were performed with buffer containing bovine serum albumin (BSA) at a very high concentration of 40 g·L−1 and also with serum. After immersing the electrode into the solution for 30 min and rinsing with PBS, the DPV peak current drops significantly due to non-specific adhesion of BSA and serum proteins, respectively. Using these as blank values for the measurements with thrombin-spiked buffer with BSA and serum, increasing concentrations of thrombin correlated to the expected decreasing DPV peak currents (
In conclusion, we have demonstrated the outstanding capabilities of directly-printed LSG electrodes to serve as electrochemical transducer in complex bioanalytical sensing environments. Our approach offers a combination of simple and scalable electrode fabrication of high-quality graphene, and a universal surface functionalization route with aptamers using PBA due to the 3D interconnected self-supporting network of LSG. Any biorecognition element can easily be immobilized on its surface and quantitative and sensitive detection is possible even in the most complex matrices such as serum. We believe that LSG has the capability to advance clinical diagnostics through miniaturized all-carbon electrode microarrays, flexible, implantable diagnostic tools, and multiplexed analysis.
Materials:
The polyimide foil for the LSG electrodes was purchased at Dasom RMS Co. LTD (Seoul, South Korea). 1-Pyrenebutyric acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide, thrombin and fetal calf serum were obtained from Sigma-Aldrich (Taufkirchen, Germany). Anti-thrombin aptamer (5′-H2N-C6-GGTTGGTGTGGTTGG-3′) was purchased from Eurofins Genomics (Ebersberg, Germany). All other chemicals were obtained from VWR International (Darmstadt, Germany) and were of analytical grade.
Electrode Fabrication:
The working electrodes (3 mm diameter) were printed on an X-660 laser cutter platform (Universal Laser Systems. Scottsdale, Ariz., USA) with a wavelength of 10.6 μm. The optimized laser power, speed, pulses per inch (PPI) and the Z-distance between laser and the sample were 0.81 W, 5.8 cm·s−1, 1000 PPI and 2 mm, respectively. All of the laser scribing experiments were performed under ambient conditions.
Electrode Characterization:
The scanning electron microscope (SEM) images were recorded on a JSM-6510 scanning electron microscope (JEOL GmbH, Freising, Germany) at 10 kV. Raman microscopy was performed on a DXR Raman microscope (Thermo Fisher Scientific GmbH, Dreieich. Germany) at 532 nm laser excitation (10 mW).
Electrode Modification:
First, LSG electrodes were modified with 5 mM 1-pyrenebutyric acid in DMSO for 60 min. Further, the electrodes were immersed in an aqueous solution 50 mM EDC and 50 mM NHS for 90 min followed by 1 μM anti-thrombin aptamer (5′-H2N-C6-GGTTGGTGTGGTTGG-3′) in an aqueous solution consisting of 100 mM NaCl and 4 mM EDTA for 3 h. The electrodes were extensively rinsed with phosphate buffered saline (PBS, pH 7.4).
Electrochemical characterization.
This was performed using a CHI 650A Electrochemical Analyzer (CH Instruments, Austin, Tex.). A Pt wire counter electrode, Ag/AgCl reference electrode, and the respective working electrode were inserted into a 10 mL three-necked round-bottom flask and a solution volume of 7 mL was used for the measurements. The electrochemical measurements of the LSG electrode was performed in phosphate-buffered saline (PBS) containing 137 mM NaCl, 2.7 mM KCl 10 mM Na2HPO4 and 1.8 mM KH2PO4 as well as 5 mM of the redox marker K3[Fe(CN)6]. The pH was adjusted to 7.4. Cyclic voltammograms were recorded from −0.3 V to 0.6 V with varying scan rates from 10 mV·s−1 to 200 mV·s−1.
Electrochemical Thrombin Detection:
The aptamer-modified LSG electrode was immersed into PBS containing thrombin at concentrations from 1 to 100 μM for 30 min. After rinsing with PBS, DPV measurements were performed with a potential ranging from −0.3 and 0.6 V vs. Ag/AgCl with a pulse width of 0.2 s and an amplitude of 50 mV. For the interference studies, bovine serum albumin was solved in PBS in a concentration of 40 g·L−1. The electrode was immersed into this solution containing thrombin at concentrations from 0 (blank) to 100 μM for 30 min. After rinsing with PBS, DPV measurements were again performed with a potential ranging from −0.3 and 0.6 V vs. Ag/AgCl with a pulse width of 0.2 s and an amplitude of 50 mV. As real samples, fetal calf serum was used. The electrode was immersed into the serum containing thrombin at concentrations from 0 (blank) to 100 μM for 30 min. After rinsing with PBS, DPV measurements were performed with the same adjustments as described above.
[a]Gold nanoparticles
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt % to about 5 wt %, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. In an embodiment, the term “about” can include traditional rounding according to significant figures of the numerical value. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
Many variations and modifications may be made to the above-described embodiments. All such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims.
This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/364,917, having the title “ON-CHIP GRAPHENE ELECTRODE, METHODS OF MAKING, AND METHODS OF USE”, filed on Jul. 21, 2016, the disclosure of which is incorporated herein in by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/IB2017/054337 | 7/18/2017 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62364917 | Jul 2016 | US |